GSE235390 4 V 2 LURBINECTEDIN HUMAN DN (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with .

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with .

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with .

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with .

Results found

Linked to

 

Label

Description

 

Gene

IKAROS family zinc finger 1

Gene

homocysteine inducible ER protein with ubiquitin like domain 1

Gene

nuclear factor of activated T cells 3

Gene

regulator of ribosome synthesis 1

Gene

SRC proto-oncogene, non-receptor tyrosine kinase

Gene

insulin receptor substrate 2

Gene

serpin family B member 2

Gene

zinc finger BED-type containing 1

Gene

translocase of inner mitochondrial membrane 9

Gene

mitochondrial elongation factor 1 upstream open reading frame

  • Gene

    IKAROS family zinc finger 1


  • Gene

    homocysteine inducible ER protein with ubiquitin like domain 1


  • Gene

    nuclear factor of activated T cells 3


  • Gene

    regulator of ribosome synthesis 1


  • Gene

    SRC proto-oncogene, non-receptor tyrosine kinase


  • Gene

    insulin receptor substrate 2


  • Gene

    serpin family B member 2


  • Gene

    zinc finger BED-type containing 1


  • Gene

    translocase of inner mitochondrial membrane 9


  • Gene

    mitochondrial elongation factor 1 upstream open reading frame

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.